Abstract
Negative and cognitive symptoms of schizophrenia remain difficult to treat. Many add-on medications to alleviate these symptoms have been proposed and investigated. In this inventory the various treatment strategies published since 1990 are being reviewed and categorised according to the pharmacological mechanism putatively involved. Notwithstanding the problems one experiences when comparing the applied measures for negative and cognitive symptoms, three clear recommendations for future research can be made viz. modulation of glutamatergic systems, blockade of serotonin 5-HT2 receptors and modulation of histaminergic systems. Strategies aimed at nAChR subtypes may also hold some promise.
Keywords: Schizophrenia, negative symptoms, cognitive dysfunction, add-on medication
Central Nervous System Agents in Medicinal Chemistry
Title: Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Volume: 8 Issue: 1
Author(s): Gerben Duisterwinkel, F. J. Bosker, A. N. Scholte-Stalenhoef, M. Vervoort and H. Knegtering
Affiliation:
Keywords: Schizophrenia, negative symptoms, cognitive dysfunction, add-on medication
Abstract: Negative and cognitive symptoms of schizophrenia remain difficult to treat. Many add-on medications to alleviate these symptoms have been proposed and investigated. In this inventory the various treatment strategies published since 1990 are being reviewed and categorised according to the pharmacological mechanism putatively involved. Notwithstanding the problems one experiences when comparing the applied measures for negative and cognitive symptoms, three clear recommendations for future research can be made viz. modulation of glutamatergic systems, blockade of serotonin 5-HT2 receptors and modulation of histaminergic systems. Strategies aimed at nAChR subtypes may also hold some promise.
Export Options
About this article
Cite this article as:
Duisterwinkel Gerben, Bosker J. F., Scholte-Stalenhoef N. A., Vervoort M. and Knegtering H., Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/187152408783790631
DOI https://dx.doi.org/10.2174/187152408783790631 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Current Medicinal Chemistry The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry Ranolazine and its Antiarrhythmic Actions
Cardiovascular & Hematological Agents in Medicinal Chemistry Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Mesoionic Oxatriazoles (MOTA): NO-Donating Characteristics and Pharmacology
Current Pharmaceutical Design Some Peculiar Effects of NO-Synthase Inhibition on the Structure and Function of Cardiovascular System
Current Pharmaceutical Biotechnology Intra-arterial Instillation of a Nociceptive Agent Modulates Cardiorespiratory Parameters Involving 5-HT3 and TRPV1 Receptors in Anesthetized Rats
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Cyclopentenone Prostaglandins as Anti-Inflammatory Agents: A Novel Therapeutic Strategy?
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Design, Synthesis, Pharmacological Evaluation and Descriptor Based Similarities Study of N,N-diphenyl-2-[4-(substituted phenyl)piperazin-1- yl]acetamides as Potential Antipsychotics
Medicinal Chemistry Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies Nitric Oxide in Asthma Therapy
Current Pharmaceutical Design Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science